Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

NaNotics to work with Mayo on nanomedicine cancer therapy

By Brian Buntz | January 4, 2022

NaNoticsNaNotics LLC (Mill Valley, California) has announced that it will work with the Mayo Clinic to develop a cancer treatment known as NaNots that works by depleting targeted pathogenic molecules from the blood. The NaNot would target a soluble form of programmed death-ligand 1 (PD-L1), a tumor-generated immune inhibitor, while ignoring membrane forms of PD-L1.

“Our team has been studying sPD-L1 for several years,” said Dr. Sean Park, an oncologist at Mayo Clinic, in a statement. “We believe it’s a key driver of immune evasion for many tumor types.”

Park said the ability to home in on soluble PD-L1 is “potentially significant.”

“We’re excited to collaborate with NaNotics and test NaNots against sPD-L1 in humans for the first time,” he added.

NaNot

NaNot image courtesy of NaNotics

NaNotics hopes to file an investigational new drug (IND) application with the FDA to begin human clinical trials within two years.

Prior animal studies have found that NaNots do not have measurable toxicity even at doses 25 to 100 times higher than the planned dose for humans.

In the collaboration, Nanotics will share its nano-depletion platform with Mayo researchers, while the Mayo Clinic will offer its own PD-L1 antibody and a transgenic mouse model that provides human sPD-L1.

NaNotics’ cofounder and CEO, Louis Hawthorne, is a molecular cloning pioneer. He has co-founded livestock and dog cloning companies.


Filed Under: Oncology
Tagged With: Mayo Clinic, NaNotics, NaNots, PD-L1, programmed death-ligand 1
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AstraZeneca/Daiichi-Sankyo
FDA approves Enhertu for HER2-low breast cancer
ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Olema Oncology
Olema Oncology’s OP-1250 could be a game-changing breast cancer drug
Merck in the Drug Discovery & Development Pharma 50
Merck halts Phase 3 Lynparza for futility

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50